Company Overview
| Stock Name | MP Cardioflow-B |
|---|---|
| Stock Code | 02160 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專注於心臟瓣膜疾病領域創新的經導管及手術解決方案的研發和商業化,主要產品為TAVI產品VitaFlow及VitaFlow II,並布局TMV、TTV等產品管線。 |
| Listing Date | 2021-02-04 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技園區張東路1601號 |
| Business Address (Hong Kong) | 香港銅鑼灣希慎道33號利園一期19樓1901室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | cardioflowmedtech.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 12.20 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 12,200 |
| Par Value | To be extracted |
| Offer Period | 2021-01-26 to 2021-01-29 |
| Global Offering Shares | 205,620,000 shares |
| HK Public Offer Shares (Initial) | 20,562,000 shares (10.0%) |
| Public Offer Lots (Initial) | 20,562lots (Pool A10,281lots,Pool B10,281lots) |
| International Placing Shares (Initial) | 185,058,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 2,366,167,020 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 38.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,508,564,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 1,000 | HK$ 12,200 |
| 2 lots | 2,000 | HK$ 24,400 |
| 3 lots | 3,000 | HK$ 36,600 |
| 4 lots | 4,000 | HK$ 48,800 |
| 5 lots | 5,000 | HK$ 61,000 |
| 6 lots | 6,000 | HK$ 73,200 |
| 7 lots | 7,000 | HK$ 85,400 |
| 8 lots | 8,000 | HK$ 97,600 |
| 9 lots | 9,000 | HK$ 109,800 |
| 10 lots | 10,000 | HK$ 122,000 |
| 15 lots | 15,000 | HK$ 183,000 |
| 20 lots | 20,000 | HK$ 244,000 |
| 25 lots | 25,000 | HK$ 305,000 |
| 30 lots | 30,000 | HK$ 366,000 |
| 35 lots | 35,000 | HK$ 427,000 |
| 40 lots | 40,000 | HK$ 488,000 |
| 45 lots | 45,000 | HK$ 549,000 |
| 50 lots | 50,000 | HK$ 610,000 |
| 60 lots | 60,000 | HK$ 732,000 |
| 70 lots | 70,000 | HK$ 854,000 |
| 80 lots | 80,000 | HK$ 976,000 |
| 90 lots | 90,000 | HK$ 1,098,000 |
| 100 lots | 100,000 | HK$ 1,220,000 |
| 100 lots | 100,000 | HK$ 1,220,000 |
| 150 lots | 150,000 | HK$ 1,830,000 |
| 150 lots | 150,000 | HK$ 1,830,000 |
| 200 lots | 200,000 | HK$ 2,440,000 |
| 200 lots | 200,000 | HK$ 2,440,000 |
| 250 lots | 250,000 | HK$ 3,050,000 |
| 300 lots | 300,000 | HK$ 3,660,000 |
| 350 lots | 350,000 | HK$ 4,270,000 |
| 400 lots | 400,000 | HK$ 4,880,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 450 lots | 450,000 | HK$ 5,490,000 |
| 500 lots | 500,000 | HK$ 6,100,000 |
| 600 lots | 600,000 | HK$ 7,320,000 |
| 700 lots | 700,000 | HK$ 8,540,000 |
| 800 lots | 800,000 | HK$ 9,760,000 |
| 900 lots | 900,000 | HK$ 10,980,000 |
| 1,000 lots | 1,000,000 | HK$ 12,200,000 |
| 2,000 lots | 2,000,000 | HK$ 24,400,000 |
| 3,000 lots | 3,000,000 | HK$ 36,600,000 |
| 3,000 lots | 3,000,000 | HK$ 36,600,000 |
| 4,000 lots | 4,000,000 | HK$ 48,800,000 |
| 5,000 lots | 5,000,000 | HK$ 61,000,000 |
| 6,000 lots | 6,000,000 | HK$ 73,200,000 |
| 7,000 lots | 7,000,000 | HK$ 85,400,000 |
| 8,000 lots | 8,000,000 | HK$ 97,600,000 |
| 9,000 lots | 9,000,000 | HK$ 109,800,000 |
| 10,281 lots | 10,281,000 | HK$ 125,428,200 |
| 261,865 lots | 261,865,757 | HK$ 3,194,762,235 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 2.08B |
| Est. Threshold | HK$ 9.37B |
| Analysis Result | HK market cap below threshold, need +351% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 28,867,237,644 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣144.5百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Profit for the year | -61,263 | -544,722 |
Balance Sheet
| Item | 2018 | 2019 | 2020-07 |
|---|---|---|---|
| Cash and cash equivalents | 61,418 | 611,873 | |
| Trade and bills receivables | 975,617 | 724,618 | |
| Inventories | 87,085 | 497,827 | |
| Total current assets | 748,891 | 983,691 | |
| Total assets | 448,897 | 826,893 | |
| Total current liabilities | 862,758 | 966,796 | |
| Total liabilities | 874,804 | 682,809 | |
| Total equity | 872,888 | 841,882 | |
| Interest-bearing borrowings | 0 | 20,000 | 0 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020-07 |
|---|---|---|---|
| Net cash from operating activities | -706,816 | -642,837 | |
| Net cash from investing activities | -740,715 | -756,871 | |
| Net cash from financing activities | 717,776 | 643,751 | |
| Net increase in cash | -696,856 | 746,752 | |
| Purchase of PP&E | -4,077 | -7,364 | -5,732 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 18.82 |
|---|---|
| First Day Open | HK$ 21.5 |
| First Day Change | 54.26% |
| First Day Volume | 186931000.0 |
| First Day Turnover | 3780700000.0 |
| Use of Proceeds | 1、30.0%(或約706.8百萬港元)將被分配予我們的核心產品(即VitaFlowTMII);
2、3.4%(或約80.1百萬港元)將被分配予我們首款商業化TAVI產品(即VitaFlowTM);
3、27.0%(或約636.1百萬港元)將被分配予我們目前產品管線的其他產品;
4、15.0%(或約353.4百萬港元)將獲分配用于為通過并購、授權引進或股權投資等方式與包括醫療器械企業及研究機構在內的全球賦能者合作擴展我們的產品組合提供資金;
5、14.6%(或約344.0百萬港元)將用于擴大我們的產能并提高我們生產VitaFlowTM及VitaFlowTMII的能力;
6、10.0%(或約235.6百萬港元)將用作我們的營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (3)
Overall Coordinators (3)
Joint Bookrunners (3)
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 3W Funds | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 2 | CDG Group Fund L.P. | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 3 | CPE Greater China Enterprises Growth Fund | 155,062,000 HKD | — | 6.20% | — | 6 months | 2021-08-04 |
| 4 | GIC Private Limited | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
| 5 | Hillhouse Funds | 116,302,600 HKD | — | 4.60% | — | 6 months | 2021-08-04 |
| 6 | Indus Funds | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 7 | Lake Bleu Prime Healthcare Master Fund Limited | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
| 8 | Snow Lake China Master Fund, Ltd. | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
| 9 | Tybourne Funds | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 10 | Woodline Master Fund LP | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 11 | WT China Focus Fund | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 12 | Yi Fang Da Brocade Inv. Limited | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 13 | 保银资产管理有限公司 | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 14 | 华夏基金管理有限公司 | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 15 | 昆仑集团有限公司 | 38,759,400 HKD | — | 1.50% | — | 6 months | 2021-08-04 |
| 16 | 泰康人寿保险有限责任公司 | 77,531,000 HKD | — | 3.10% | — | 6 months | 2021-08-04 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 羅七一 | — |
| Company Secretary | 李香梅、陳濼而 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東微創醫療通過Shanghai MicroPort於上市後持有約45.59%權益;上海鏵浩8.10%、中金康瑞7.67%、Qianyi Investment 6.34%。 |
|---|




